Table 4. All-causality non-ocular adverse events in ⩾5% of subjects (year 3, safety population) (n (%)).

Adverse event (system organ class)	All subjects who received active therapy for 3 years n = 161
Investigations*	41 (25)
Infections and infestations	29 (18)
Respiratory, thoracic and mediastinal disorders	24 (15)
Gastrointestinal disorders	23 (14)
Musculoskeletal and connective tissue disorders	20 (12)
Nervous system disorders	18 (11)
Cardiac disorders	17 (11)
Injury, poisoning and procedural complications	16 (10)
Vascular disorders	15 (9)
Skin and subcutaneous tissue disorders	14 (9)
Metabolism and nutrition disorders	10 (6)
Neoplasms benign, malignant and unspecified	9 (6)

*The majority of these events were “increased intraocular pressure (IOP)”; the investigators were required to report an IOP of ⩾30 mm Hg at 30 min after injection as an adverse event.